Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q4 2023 Earnings Conference Call February 20, 2024 8:00 AM ET Company Participants Mark Jacobson - Chief Operating Officer Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer Ari Maizel - Executive Vice President and Head of Commercial Hunter Murdock - General Counsel Conference Call Participants Leonid Timashev - RBC Capital Markets Charles Duncan - Cantor Fitzgerald Ash Verma - UBS Jason Gerberry - Bank of America David Amsellem - Piper ...

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 39.67%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.24 per share when it actually produced a loss of $1.32, delivering a surprise of -6.45%.Over the last four quarters, th ...

Investors are always looking for stocks that are poised to beat at earnings season and Axsome Therapeutics, Inc. (AXSM) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Axsome is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty g ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Axsome Therapeutics (AXSM) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 20, 2024, might help the stock move higher if these key numbers are bet ...

In the investing world, a two-bagger refers to a stock that gains 100% -- that is, it doubles your initial capital. Doing so in a mere five years is no easy feat. It requires a compound annual growth rate (CAGR) of about 14.9% -- which, incidentally, is pretty much what the S&P 500 has posted in the past half-decade.However, this has been an unusual period; the broader market's average annual return is usually below that level. So returns of this type are by no means a guarantee. But if I had to bet on two ...

NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year of 2023 on Tuesday, Feb. 20, 2024, before the opening of the U.S. financial markets. Axsome's management team will host a conference call at 8:00 a.m. Eastern Time on Feb. 20, 2024, to discuss these result ...

NEW YORK, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year of 2023 on Tuesday, Feb. 20, 2024, before the opening of the U.S. financial markets. Axsome’s management team will host a conference call at 8:00 a.m. Eastern Time on Feb. 20, 2024, to discuss these resul ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2023 Earnings Conference Call November 6, 2023 8:00 AM ET Company Participants Mark Jacobson - Chief Operating Officer Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer Lori Englebert - Executive Vice President, Commercial and Business Development Hunter Murdock - General Counsel Conference Call Participants Charles Duncan - Cantor Fitzgerald Rudy Li - Leerink Partners Vikram Purohit - Morgan Stanley David Amsellem - Piper Sandler Jas ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-37635 AXSOME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 45-4241907 (State or ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2023 Earnings Conference Call August 7, 2023 8:00 AM ET Company Participants Mark Jacobson - IR Herriot Tabuteau - CEO Nick Pizzie - CFO Lori Englebert - EVP, Commercial and Business Development Conference Call Participants Charles Duncan - Cantor Fitzgerald Raghuram Selvaraju - H.C. Wainwright Joon Lee - Truist Securities Jason Gerberry - Bank of America David Amsellem - Piper Sandler Vikram Purohit - Morgan Stanley Yatin Suneja - Guggenheim Partners Joseph Thome ...